Ronald Kirk Huntsman

CIK: 0001835498

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (50.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

VVOS

Vivos Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (2 total)

VVOS
Vivos Therapeutics, Inc.
Jun 30, 2026
Other(J)
Indirect
85.9K shares at avg. $0.58$50K
VVOS
Vivos Therapeutics, Inc.
Nov 26, 2024
Award(A)
Stock Option (Right to Buy)
Direct
315.4K shares at avg. $2.64-

		Type	Shares	Price		Ownership
Jun 30, 2026	VVOS Vivos Therapeutics, Inc.	Other(J)	85,910	$0.58	$50,000	Indirect
Nov 26, 2024	VVOS Vivos Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	315,421	$2.64	-	Direct

1-2 of 2 transactions

About Huntsman Ronald Kirk

Huntsman Ronald Kirk (SEC CIK 0001835498) files insider reports with the SEC as Chief Executive Officer of Vivos Therapeutics, Inc. (VVOS).

Signal8 holds 2 ownership filings by Huntsman Ronald Kirk, all Form 4s, filed between Nov 27, 2024 and Sep 18, 2026. Those filings report 2 transactions, from Nov 26, 2024 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Huntsman Ronald Kirk's filings is in LITTLETON, CO.

Recent filings by Huntsman Ronald Kirk

Jun 30, 2026: Other transaction of VVOS shares (Form 4, code J).
Nov 26, 2024: Grant or award of VVOS derivative securities (Form 4, code A).

Other insiders filing for Vivos Therapeutics, Inc. (VVOS)

Krammer Anja B, Director
Lindsay Mark F., Director
Green Ralph Elias, Director
SOKOLOW LEONARD J, Director
JOHNSON GREGG C, Director
Amman Bradford K., Principal Accounting Officer

How to read Form 4 transaction codes